Oncology Center, International Medical Center, Jeddah, 21451, Kingdom of Saudi Arabia.
Future Oncol. 2020 Apr;16(10):585-596. doi: 10.2217/fon-2020-0057. Epub 2020 Mar 13.
Poly(ADP-ribose) polymerase inhibitors (PARPIs) improved progression-free survival among patients with recurrent ovarian cancer. This meta-analysis examined the effectiveness of PARPIs as maintenance strategy for newly diagnosed patients with advanced high-grade ovarian cancer with or without mutations. Using defined selection criteria, a literature search identified four eligible randomized clinical trials involving 2386 patients. Compared with placebo maintenance, PARPIs achieved a 46% reduction in the risk of progression or death as compared with placebo (hazard ratio: 0.54; 95% CI: 0.39-0.73; p < 0.0001). That benefit was shown in all clinical subgroups: among those with mutation, with negative/unknown mutation, and in those with homologous recombination deficient tumors. Data about the effect on overall survival are still premature. In patients with newly diagnosed advanced ovarian cancer, PARPIs maintenance after standard therapy achieved a significant improvement in progression-free survival as compared with placebo, overall and in all subgroups.
聚（ADP-核糖）聚合酶抑制剂（PARPIs）改善了复发性卵巢癌患者的无进展生存期。这项荟萃分析研究了 PARPIs 作为新诊断的高级别卵巢癌伴或不伴突变患者的维持治疗策略的有效性。使用明确的选择标准，通过文献检索确定了四项符合条件的随机临床试验，涉及 2386 名患者。与安慰剂维持治疗相比，PARPIs 降低了 46%的进展或死亡风险（风险比：0.54；95%置信区间：0.39-0.73；p<0.0001）。这种获益在所有临床亚组中均得到证实：包括 突变、 突变阴性/未知和同源重组缺陷型肿瘤患者。关于对总生存期影响的数据仍不成熟。在新诊断的晚期卵巢癌患者中，与安慰剂相比，标准治疗后接受 PARPIs 维持治疗在无进展生存期方面取得了显著改善，总体和所有亚组中均如此。
